

Title Dermatological treatments

Reference Number: RDF2457-24

Date of Response: 16/04/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

- 1) *How many patients were treated in the last 4 months (December 2023 to March 2024) by the dermatology department with each of the following products:*

Answers:

Treatment	Patients
Abrocitinib	9
Acitretin	117
Alitretinoin	19
Azathioprine	0
Baricitinib	*<5
Ciclosporin	17
Dupilumab	162
Lebrikizumab	0
Methotrexate	247
Mycophenolate mofetil	14
Pimecrolimus	26
Phototherapy (UVB or PUVA) – <i>for Atopic Dermatitis only</i>	*<5
Tacrolimus ointment	70
Tralokinumab	13
Upadacitinib	8

- 2) *Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:*

Answers:

Age Group	Patients
Age 6-11	19
Age 12-17	16
Age 18 and above	668

*<5 - Section 40(2):

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this

applies is very low. This and the fact that the data requested relates to the RDUH NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that Section 40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.